Matthias Tschöp
Matthias Tschöp is the head of the Health Research area at the Helmholtz Association in Germany and is known for his groundbreaking work in obesity and metabolic diseases. He played a crucial role in the development of advanced treatments like Tirzepatide, which continue to reshape the landscape of obesity therapy.
Global Media Ratings
Countries Mentioned
| Country | Mentions | Sentiment | Dominance | + Persistence | x Population | = Reach | x GDP (millions) | = Power |
|---|---|---|---|---|---|---|---|---|
| Germany | 2 | 8.50 | 0.09% | +10% | 83,783,942 | 86,905 | $3,845,000 | 3,988$ |
| Switzerland | 1 | 8.00 | 0.07% | +0% | 8,654,622 | 5,985 | $700,000 | 484$ |
| Totals | 3 | 92,438,564 | 92,890 | $4,545,000 | 4,472$ |
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
Germany:
Matthias Tschöp is the new president of Ludwig Maximilians University in Munich, returning to the institution where he studied.
8
Germany:
Matthias Tschöp is a renowned scientist known for his work in diabetes and obesity research and has been appointed as the new president of Ludwig-Maximilians-Universität.
9
Switzerland:
Matthias Tschöp is the head of the health research area at the Helmholtz Association and was significantly involved in the development of Wegovy's successor.
8